Kangma Biotechnology
Next-generation biotech company leveraging DNA-to-Protein (D2P) technology to enable industrial-scale protein production
About Kangma Biotechnology
Kangma (Shanghai) Biotechnology Co., Ltd., operating under the trade name OurProteinFactory.com, is a biotechnology firm established in 2015. The company is positioned to address the market for high-value protein synthesis and disease diagnostics. Its core operations are centered around a proprietary, patented D2P (DNA-to-Protein) technology.
The company's primary offering, the ProteinFactory system, is an engineered, eukaryote-based, cell-free protein synthesis platform. This system consolidates the entire central dogma of molecular biology—DNA duplication, RNA transcription, and protein translation—into a single in-vitro process. A key operational advantage is its ability to produce folded proteins at room temperature (20-30°C) in approximately three hours, a significant time reduction compared to traditional methods. The technology reportedly increases protein yield by 10 to 1,000 times compared to other cell-free kits while substantially lowering costs. Kangma Biotechnology serves a client base primarily composed of academic and research institutions, providing tools for teaching and research purposes.
Revenue is generated through the sale of its ProteinFactory kits and a suite of related services. The business model includes offering standardized kits (e.g., Array, NMR, High Yield) and a customization service where clients can provide a protein sequence to receive a bespoke kit for its synthesis. This is facilitated through its e-commerce platform on OurProteinFactory.com and a dedicated mobile app, 'Proteinn'. Beyond protein synthesis, the company is developing a broader platform incorporating big data analysis, cloud computing, and AI services related to genes and proteins, alongside developing disease diagnosis microchips.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 21.0/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotechnology, Medical & Healthcare, Health Diagnostics, Synthetic Biology, DT and LS, science-based
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES C✓Equity / VC | Apr 2025 | $28M | $110M | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for Kangma Biotechnology is 460 monthly website visits, down 43.2% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Kangma Biotechnology in its local ecosystem
The Kangma Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Kangma Biotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Kangma Biotechnology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







